T
Taroh Satoh
Researcher at Osaka University
Publications - 190
Citations - 8238
Taroh Satoh is an academic researcher from Osaka University. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 27, co-authored 190 publications receiving 5705 citations. Previous affiliations of Taroh Satoh include Kindai University.
Papers
More filters
Journal ArticleDOI
Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.
Yasuyuki Kawamoto,Takashi Meguro,Satoshi Yuki,Hiroshi Nakatsumi,Takahide Sasaki,Kazuteru Hatanaka,Minoru Uebayashi,Ichiro Iwanaga,Nobuhiko Abe,Michio Nakamura,Hiroyuki Okuda,Kazunori Eto,Ayane Oba,Masakazu Abe,Koji Oba,Taroh Satoh,Yuh Sakata,Naoya Sakamoto,Yoshito Komatsu +18 more
TL;DR: This study assessed the efficacy and safety of Tmab with irinotecan in HER2-positive gastric cancer pts previously treated with Tmabs and failed and the response rate (RR) and secondary endpoints were progression-free survival (PFS) and six-month survival rate.
Journal ArticleDOI
The real-world data in patients with advanced gastric cancer treated with ramucirumab combination chemotherapy.
Akie Kimura,Daisuke Sakai,Toshihiro Kudo,Naohiro Nishida,Aya Katou,Chiaki Inagaki,Toru Otsuru,Koji Tanaka,Yasuhiro Miyazaki,Tomoki Makino,Tsuyoshi Takahashi,Yukinori Kurokawa,Makoto Yamasaki,Yuichiro Doki,Masaki Mori,Taroh Satoh +15 more
TL;DR: In subgroup analysis, good response was observed in the group of prior nivolumab or pembrolizumab, and NLR was prognostic factor for PFS, while it wasn’t show the relevance to OS because of the influence of after ramucirumab therapy.
Journal ArticleDOI
Microsatellite instability status in metastatic colorectal cancer and effect of immune checkpoint inhibitors on survival in MSI-high metastatic colorectal cancer
Wataru Okamoto,Yoshiaki Nakamura,Manabu Shiozawa,Yoshito Komatsu,Tadamichi Denda,Hiroki Hara,Yoshinori Kagawa,Yukiya Narita,Hisato Kawakami,Taito Esaki,Tomohiro Nishina,Naoki Izawa,Koji Ando,Toshikazu Moriwaki,Takeshi Kato,Fumio Nagashima,Taroh Satoh,Shogo Nomura,Tadashi Yoshino,Kiwamu Akagi +19 more
TL;DR: In this article, Tumor mismatch repair (MMR) predicts benefit of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC).
Journal ArticleDOI
Retrospective study of ramucirumab in patients with advanced gastric cancer.
Daisuke Sakai,Toshihiro Kudo,Aya Kato,Koji Tanaka,Yasuhiro Miyazaki,Tomoki Makino,Tsuyoshi Takahashi,Yukinori Kurokawa,Makoto Yamasaki,Shuji Takiguchi,Masaki Mori,Yuichiro Doki,Taroh Satoh +12 more
TL;DR: This retrospectively investigated the efficacy and safety of ramucirumab in the patients with advanced gastric cancer in the institution from July 2015 to September 2016, finding that the drug was effective as second line chemotherapy and effective in combination with paclitaxel.
Journal ArticleDOI
Safety and efficacy of regorafenib in Japanese patients with metastatic colorectal cancer (mCRC) in clinical practice: Interim result from postmarketing surveillance (PMS).
Yoshito Komatsu,Kei Muro,Kensei Yamaguchi,Hiroyuki Uetake,Taroh Satoh,Takayuki Yoshino,Toshirou Nishida,Naoya Yamazaki,Hajime Takigawa,Yoko Hamada,Masayuki Chosa,Toshiyuki Sunaya,Yuka Yamamoto,Y. Ito,Toshiaki Watanabe,Kenichi Sugihara +15 more
TL;DR: A Japanese PMS has been conducted to assess the safety and efficacy of REG for the treatment of mCRC in clinical practice, and 545 pts were evaluable forSafety and efficacy.